Semaglutida apresenta resultados sólidos de perda de peso para adultos acima de 65 anos

12 de maio de 2026

Reportado por IA

Uma nova análise de ensaios clínicos indica que a semaglutida, o princípio ativo do Ozempic e do Wegovy, ajuda adultos mais velhos com obesidade a perder uma quantidade substancial de peso e a melhorar marcadores de saúde cardíaca. As descobertas vêm de dados de participantes com 65 anos ou mais que receberam a medicação semanalmente em conjunto com mudanças no estilo de vida.

Pesquisadores liderados pelo Prof. Luca Busetto, da Universidade de Pádua, examinaram resultados dos ensaios STEP 1, 3, 4, 5, 8 e 9. A análise concentrou-se em 358 adultos com 65 anos ou mais com obesidade, mas sem diabetes. Destes, 248 tomaram semaglutida 2,4 mg, enquanto 110 receberam um placebo ao longo de 68 semanas.

Study finds people who use Ozempic-like drugs for weight loss face added stigma

05 de maio de 2026 Reportado por IA Imagem gerada por IA Verificado

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

Study links Ozempic to lower depression and anxiety risks

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

20 de março de 2026 Reportado por IA

A real-world study of nearly 8,000 patients by Cleveland Clinic researchers shows that stopping injectable semaglutide or tirzepatide often does not lead to major weight regain. Many participants maintained or continued losing weight by restarting treatment, switching medications, or using lifestyle support. This differs from clinical trials where rapid regain was observed.

Saúde

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Saúde

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Saúde

Gut reset procedure limits weight regain after stopping Ozempic

Trojan horse obesity drug boosts weight loss in mice

Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

25 de abril de 2026 Reportado por IA

Young Indians are turning to diabetes drugs Ozempic and Mounjaro for rapid weight loss before weddings and job interviews, as experts warn of cosmetic misuse, grey market dangers, and rising lookism. These GLP-1 drugs are meant for obesity and diabetes, not vanity purposes, doctors emphasize.

Study recommends treatment for all children with obesity

A new Karolinska Institutet study finds that children with moderate obesity face higher risks of type 2 diabetes, high blood pressure, and lipid disorders in adulthood, even without apparent risk markers. Researchers urge treatment for all such children.

Testosterone gel plus exercise may limit visceral fat gain in older women recovering from hip fractures

08 de maio de 2026 Reportado por IA Verificado

A University of Connecticut-led clinical trial found that older women recovering from a recent hip fracture who used a topical testosterone gel alongside a structured exercise program did not experience the typical rise in visceral abdominal fat seen during recovery. Researchers followed participants for six months and assessed body composition with imaging scans.

quinta-feira, 09 de abril de 2026, 23:54h

Semaglutida apresenta resultados sólidos de perda de peso para adultos acima de 65 anos

Artigos relacionados

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Study links Ozempic to lower depression and anxiety risks

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Gut reset procedure limits weight regain after stopping Ozempic

Trojan horse obesity drug boosts weight loss in mice

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

Study recommends treatment for all children with obesity

Testosterone gel plus exercise may limit visceral fat gain in older women recovering from hip fractures

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

Study finds prediabetes remission possible without weight loss

GLP-1 weight loss drugs boost premium chocolate sales

Animal study raises new questions about gut effects of SNAC, an ingredient used in oral semaglutide tablets

New study offers hope for weight loss drugs against alcoholism

Cochrane review finds intermittent fasting no better for weight loss

AI digital twins help manage diabetes and obesity

India today investigation reveals lax drug norms for weight loss injections

Cochrane reviews assess GLP-1 drugs for obesity treatment

Este site usa cookies